Not all populations have access to regular dermatologist visits for education, preventative care, and skin cancer–risk screening. One in 5 Americans will develop skin cancer by the age of 70 years.

 Given this high prevalence of skin cancer, pharmacists have an impactful role—to take action within the community, incorporate screening for skin cancer risk, and educate the public concerning the need for photoprotection.

 The Skin Cancer Foundation recommends sunscreen application as an effective aid in preventing sun-induced damage to the skin, including sunburn and possible premature aging. When used regularly according to label directions, certain products may also help reduce the potential risk of skin cancer due to overexposure to sunlight.

Skin cancer affects people of all skin types. The Fitzpatrick system classifies skin type based on how much pigment is found in the skin and how the skin reacts to exposure to the sun:

type I: always burns, never tans (palest; freckles);

type II: usually burns, tans minimally (light colored,
but darker than fair);

type III: sometimes burns mildly, tans uniformly (golden honey or olive);

type IV: burns minimally, always tans well (moderately brown);

type V: very rarely burns, tans very easily (dark brown); and

type VI: never burns (deeply pigmented dark brown or black).

Anyone can develop skin cancer, but established factors (eg, type I and II classification, having > 50 moles, a family or personal history of skin cancer) put individuals at a greater risk.

 Additionally, certain medications may cause the skin to be more sensitive or to react unusually to UV-A/UV-B light exposure (ie, photosensitivity).

There is a lack of identification and recognition of skin cancers in people with skin types IV to VI

 Educational materials for both patients and health care professionals traditionally demonstrate images with examples of basal cell carcinomas on skin types I to III.

 As 50% of basal cell carcinomas are pigmented brown in color, skin cancer warning signs often go undetected because they look different on darker toned skin. As a result, skin cancer is often diagnosed too late and at a stage that is difficult to treat in people with a darker skin tone.

Pharmacists can play a major role in education, especially as it relates to addressing individual skin care needs, preventing skin cancer across all skin types, and guiding the selection of broad spectrum sun protection products available in the pharmacy.

PHOTOSENSITIZING PRESCRIPTION MEDICATIONS

Several photosensitizing prescription medicationsare dispensed regularly in the pharmacy, like acne medications (eg, doxycycline, spironolactone, oral contraceptives, topical retinoids, isotretinoin), antibiotics (eg, tetracyclines, sulfonamides), and hormonal contraceptives.

 Commonly used OTC medications can also be photosensitizing such as nonsteroidal anti-inflammatory drugs (particularly naproxen).

Skin photoprotection is top of mind during the warm weather seasons, but there are several opportunities for pharmacists to advocate for protection year-round. When dispensing prescription photosensitizing medications, pharmacists can recommend broad spectrum sunscreen products. As photosensitizing acne medications with isotretinoin can cause skin drying effects, pharmacists can suggest sunscreen products with added hydrating ingredients.

 contains information to support education concerning select CeraVe

 These sunscreen products are formulated for sensitive skin types, offer a range of sun protection factor (SPF) values for individual needs, and contain ingredients that provide additional benefits (eg, ceramide, antioxidants, hydrating ingredients).

 sunscreens are developed with dermatologists; they are the only 100% mineral-based sunscreens that contain 3 essential ceramides (ceramides 1, 3, and 6-II) to form a protective barrier on the skin’s surface to avoid irritation of sensitive skin and to lock in moisture after application.

 Moisturizing ingredients are provided to the skin’s surface through a time-released, multivesicular emulsion technology that delivers concentric layers of oil-in-water emulsions. These layers slowly unfold upon application, continually releasing ingredients for the skin to absorb, as needed. These ceramide-containing sunscreens are formulated to help maintain and restore the skin’s natural protective barrier against damage induced by UV radiation.

Ceramides are lipids found naturally in the skin; they make up 50% of the stratum corneum. They are essential to support the skin barrier and retain moisture. When ceramide levels are low, the skin barrier is weakened, and moisture can escape. Ceramide deficiency is associated with atopic dermatitis, acne, and other dermatologic conditions.

 Additionally, people with skin types IV to VIhave ceramide deficiencies, and they may benefit from ceramide-containing formulations.

AM Facial Moisturizing Lotion with Sunscreen (SPF 30)

 are lightweight daily moisturizers with chemical SPF filters, which tend to be easier to rub into the skin and less likely to leave a white residue.

’s Anthelios has several sunscreen products available aimed to meet the needs of all ages, skin types, and tones, such as 

Anthelios Melt-in Milk Sunscreen for Face & Body SPF 60

Anthelios Mineral Tinted Sunscreen for Face SPF 50

. Anthelios sunscreen products are formulated with Cell-Ox Shield

 technology, which combines photostable UV-A/UV-B filters (eg, avobenzone, homosalate, octisalate, octocrylene) plus antioxidants (eg, vitamin E, vitamin C, senna alata) to defend skin cells against damaging free radicals caused by exposure to UV rays and the environment.

Increasing evidence suggests that the skin microbiome may play a role in atopic dermatitis, psoriasis, and acne.

Toleriane Double Repair Face Moisturizer UV (SPF 30)

 Prebiotic Thermal Spring Water to help foster a balanced skin microbiome.

 This core ingredient contains a combination of minerals, trace elements, and a high concentration of the natural antioxidants selenium and strontium that help soothe skin.

For a description of the ingredients in CeraVe® and La Roche-Posay® Anthelios sun care products (eg, Cell-Ox Shield® Technology, vitamin E, vitamin C, senna alata, dimethicone, silica, La Roche-Posay® Thermal Spring Water, glycerin, panthenol [provitamin B5], iron oxides, and perlite), visit 

Skin cancer facts & statistics. Skin Cancer Foundation. Updated January 2022. Accessed February 8, 2022. https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/ancer-information/skin-cancer-facts/

All about sunscreen. Skin Cancer Foundation. Updated May 2021. Accessed February 8, 2022. https://www.skincancer.org/skin-cancer-prevention/sun-protection/sunscreen/

Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. 

. 1988;124(6):869-871. doi:10.1001/archderm.124.6.869

Oakley A. Fitzpatrick skin phototype. DermNet NZ. 2012. Accessed February 8, 2022. https://dermnetnz.org/topics/skin-phototype

New AAD survey: only a third of Americans are concerned about skin cancer despite nearly 70% having at least one risk factor. American Academy of Dermatology Association. June 15, 2021. Accessed February 8, 2022. https://www.aad.org/news/new-aad-survey-shows-americans-unaware-skin-cancer-risk

Skin cancer: what are the risk factors for skin cancer? CDC. Reviewed April 28, 2021. Accessed February 8, 2022. https://www.cdc.gov/cancer/skin/basic_info/risk_factors.htm

Are you at risk for skin cancer? Skin Cancer Foundation. April 8, 2021. Accessed February 8, 2022. https://www.skincancer.org/blog/are-you-at-risk-for-skin-cancer/

Photosensitivity & your skin. Skin Cancer Foundation. Updated May 2021. Accessed February 8, 2022. https://www.skincancer.org/risk-factors/photosensitivity/

Tsai J, Chien AL. Photoprotection for skin of color. 

. 2022:1-11. doi:10.1007/s40257-021-00670-z

Ask the expert: is there a skin cancer crisis in people of color? Skin Cancer Foundation. July 5, 2020. Accessed February 8, 2022. https://www.skincancer.org/blog/ask-the-expert-is-there-a-skin-cancer-crisis-in-people-of-color/

Skin cancer and skin of color. Skin Cancer Foundation. Updated January 2022. Accessed February 8, 2022. https://www.skincancer.org/skin-cancer-information/skin-cancer-skin-of-color/

Gloster HM Jr, Neal K. Skin cancer in skin of color. 

. 2006;55(5):741-760. doi:10.1016/j.jaad.2005.08.063

Medications and other agents that increase sensitivity to light. Wisconsin Department of Health Services. Revised December 21, 2015. Accessed February 8, 2022. https://www.dhs.wisconsin.gov/radiation/medications.htm

Crosby KM. Chapter 39: prevention of sun-induced skin disorders. In: Krinsky DL, ed. 

Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care. 20th Edition

. American Pharmacists Association; 2020. APhA Pharmacy Library. Accessed February 23, 2022. https://pharmacylibrary.com/doi/full/10.21019/9781582123172.ch39

Isotretinoin: overview. American Academy of Dermatology Association. Updated December 15, 2021. Accessed February 8, 2022. https://www.aad.org/public/diseases/acne/derm-treat/isotretinoin

Ultra-light moisturizing lotion SPF 30. CeraVe. Accessed February 8, 2022. https://www.cerave.com/skincare/moisturizers/ultra-light-
moisturizing-lotion-spf-30

AM facial moisturizing lotion with sunscreen. CeraVe. Accessed February 8, 2022. https://www.cerave.com/skincare/moisturizers/am-facial-
moisturizing-lotion-with-sunscreen

Toleriane double repair facial moisturizer with SPF. La Roche-Posay. Accessed February 8, 2022. https://www.laroche-posay.us/our-products/face/face-moisturizer/toleriane-double-repair-facial-moisturizer-with-spf-3337875545846.html

Anthelios clear skin oil free sunscreen SPF 60. La Roche-Posay. Accessed February 8, 2022. https://www.laroche-posay.us/our-products/sun/face-sunscreen/anthelios-clear-skin-oil-free-sunscreen-spf-60-3606000430488.html

Anthelios melt-in milk sunscreen for face & body SPF 100. La Roche-Posay. Accessed February 8, 2022. https://www.laroche-posay.us/our-products/sun/body-sunscreen/anthelios-melt-in-milk-sunscreen-for-face-body-spf-100-3606000546103.html

Anthelios ultra light fluid facial sunscreen SPF 60. La Roche-Posay. Accessed February 8, 2022. https://www.laroche-posay.us/our-
products/sun/face-sunscreen/anthelios-ultra-light-fluid-facial-sunscreen-spf-60-883140012993.htm

Hydrating mineral sunscreen SPF 50 body lotion. CeraVe. Accessed February 8, 2022. https://www.cerave.com/sunscreen/body/hydrating-
mineral-sunscreen-body-lotion-spf-50

Hydrating mineral sunscreen SPF 50 face lotion. CeraVe. Accessed February 8, 2022. https://www.cerave.com/sunscreen/face/hydrating-
mineral-sunscreen-face-lotion-spf-50

Hydrating mineral sunscreen SPF 30 face sheer tint. CeraVe. Accessed February 8, 2022. https://www.cerave.com/sunscreen/face/hydrating-
mineral-sunscreen-spf-30-face-sheer-tint

Anthelios mineral tinted sunscreen for face SPF 50. La Roche-Posay. Accessed February 8, 2022. https://www.laroche-posay.us/our-products/sun/tinted-sunscreen/anthelios-mineral-tinted-sunscreen-for-face-spf-50-883140020899.html

Anthelios mineral zinc oxide sunscreen SPF 50. La Roche-Posay. Accessed February 8, 2022. https://www.laroche-posay.us/our-products/sun/face-sunscreen/anthelios-mineral-zinc-oxide-sunscreen-spf-50-883140000907.html

Draelos ZD. Improving compliance in acne treatment: benzoyl peroxide considerations. 

Dumbuya H, Yan X, Chen Y, et al. Efficacy of ceramide-containing formulations on UV-induced skin surface barrier alterations. 

. 2021;20(4):S29-S35. doi:10.36849/JDD.2021.589E

Borodzicz S, Rudnicka L, Mirowska-Guzel D, Cudnoch-Jedrzejewska A. The role of epidermal sphingolipids in dermatologic diseases. 

. 2016;15:13. doi:10.1186/s12944-016-0178-7

Lynde CW, Andriessen A. A cohort study on a ceramide-containing cleanser and moisturizer used for atopic dermatitis. 

Muizzuddin N, Hellemans L, Van Overloop L, Corstjens H, Declercq L, Maes D. Structural and functional differences in barrier properties of African American, Caucasian and East Asian skin. 

. 2010;59(2):123-128. doi:10.1016/j.jdermsci.2010.06.003

Is sunscreen safe? American Academy of Dermatology Association. Updated February 21, 2019. Accessed February 8, 2022. https://www.aad.org/public/everyday-care/sun-protection/sunscreen-patients/is-sunscreen-safe

Poljšak B, Dahmane R. Free radicals and extrinsic skin aging. 

. 2012;2012:135206. doi:10.1155/2012/135206

Dunaway S, Odin R, Zhou L, Ji L, Zhang Y, Kadekaro AL. Natural antioxidants: multiple mechanisms to protect skin from solar radiation. 

. 2018;9:392. doi:10.3389/fphar.2018.00392

Bernstein EF, Sarkas HW, Boland P, Bouche D. Beyond sun protection factor: an approach to environmental protection with novel mineral coatings in a vehicle containing a blend of skincare ingredients. 

. 2020;19(2):407-415. doi:10.1111/jocd.13007

Zeichner J, Seite S. From probiotic to prebiotic using thermal spring water. 

Grice EA, Segre JA. The skin microbiome. 

. 2011;9(4):244-253. doi:10.1038/nrmicro2537

Articles

Guide to Preventative Skin Care and Importance of Sun Protection for the Community Pharmacist

THE GOAL OF EPILEPSY TREATMENT is to help patients achieve 100% seizure reduction (zero seizures) with minimal adverse events (AEs). Unfortunately, many patients with epilepsy continue to have uncontrolled seizures despite taking multiple antiseizure medications (ASMs).

 Therefore, dose adjustments and medication changes are often necessary to find combinations that help reduce seizure frequency and minimize AEs, a practice referred to as rational polypharmacy. Specific guidance on how to combine ASMs is lacking, however, due in large part to the widely individualized nature of epilepsy treatment. In addition, the availability of several newer ASMs has provided an even greater number of possible ASM combinations.

The typical strategy for polytherapy treatment in patients with uncontrolled seizures includes combining ASMs with different mechanisms of action, essentially on a trial-and-error basis, while monitoring and adjusting for AEs and efficacy. Should intolerable AEs occur when a new ASM, particularly one that has been recently approved, is added to the treatment regimen, there is a tendency for the last drug added to be the first one down-titrated or removed before moving on to a different therapeutic combination or reverting to the previous regimen. This practice may not be the most beneficial since the rationale for adding on the new ASM was failure of the previous regimen. Instead, it may be sounder to examine the potential pharmacokinetic/pharmacodynamic interactions between the existing regimen and the newly added ASM and adjust the pre-existing regimen, since it was not successful in achieving zero seizures/seizure freedom. During titration of the new ASM, for example, the existing ASMs can be down-titrated, as needed, to minimize the AEs of the new combination until an acceptable therapeutic balance is achieved. The dose of the newly added ASM will of course vary from patient to patient and will also vary based on the existing combination of ASMs.

A case in point is the use of adjunctive cenobamate, which is approved by the FDA under the brand name XCOPRI (cenobamate tablets) CV, for the treatment of adult patients with focal seizures. When cenobamate was added to existing ASM regimens, approximately 20% more patients vs those on a placebo regimen achieved seizure freedom,

 compared with 0.8% to 5.4% more patients than placebo for other adjunctive ASMs (pooled analyses).

 Yet many health care providers will discontinue a newly added ASM at the first sign of tolerability concerns and revert to the previous regimen, potentially limiting the patient’s opportunity to reach seizure freedom. Recent post hoc analyses of study data published in 

 provide support for a more rational approach to concomitant ASM dose adjustments when adding cenobamate.




CENOBAMATE POST HOC PHASE 3 STUDY RESULTS



A large (N = 1340), long-term, phase 3, open-label study

 (C021) was conducted to focus on safety; however, given the importance of data on long-term seizure control in patients with uncontrolled seizures, a C021 protocol amendment allowed post hoc collection of seizure data from a subset of 10 US C021 study sites (n = 240).

 One post hoc analysis from this subset of patients examined how dose adjustments to baseline concomitant ASMs affected tolerability, efficacy, and retention of patients receiving adjunctive cenobamate.

 While cenobamate monotherapy was not permitted during the study, most concomitant ASMs were adjusted to lower doses, and in some cases were removed completely, thereby lowering the total drug load, alleviating AEs, and most importantly, allowing many patients to achieve long-term seizure freedom.



Results from the post hoc analyses that looked at specific ASMs across regimens

 showed that greater percentages of patients remained on cenobamate than discontinued cenobamate for almost all concomitant ASMs taken at baseline, with approximately 70% of patients continuing treatment with cenobamate for most baseline ASMs.

 Dosages of concomitant ASMs were reduced most often because of AEs, such as somnolence, dizziness, ataxia, and fatigue, and the dose reductions were greater in patients who continued treatment with cenobamate vs those who discontinued cenobamate.

 These results suggest that patients who received dose adjustments of concomitant ASMs were more likely to stay on cenobamate and achieve better seizure control.

Further analysis found that doses of phenytoin, phenobarbital, clobazam, valproate, and lacosamide were decreased by investigators earliest in the study, during the 12-week titration phase for cenobamate.

 In spite of these concomitant ASM reductions, increased seizure control was observed early, during the first 4 weeks of titration, in many patients in the overall cohort, starting at cenobamate doses of 12.5 mg to 25 mg.

 Most of the early dose reductions were likely in response to pharmacokinetic drug interactions that had led to alterations in drug exposure and subsequent issues with tolerability.

Some ASMs, as in the case of clobazam, can and should be reduced proactively because of known drug-drug interactions with cenobamate.

 Other concomitant ASMs, such as carbamazepine, oxcarbazepine, and eslicarbazepine, were reduced later (or more reactively) in the study, during the early maintenance phase.

 These concomitant dose reductions likely were made later because there were few or no pharmacokinetic interactions with these drugs. Regardless of dose reductions or which concomitant ASM patients were taking, retention (ie, percentages of patients who remained throughout the study) was high, ranging between approximately 72% and 79% for the most common baseline ASMs, supporting the efficacy of cenobamate.



Robust efficacy, including high rates of 100% seizure reduction, was also observed. Among all patients, 25.8% experienced 100% seizure reduction for at least 12 months and the mean duration of 100% seizure reduction for these patients was 23.5 months.

 Reducing doses of the concomitant ASMs may have improved tolerability, allowing for cenobamate to be titrated to its optimal dose and thereby increasing the overall efficacy.



Results from this post hoc analysis provide guidance on how various concomitant ASMs may be adjusted while adding on cenobamate. They also provide further insight into the use of rational polytherapy for patients with epilepsy. The goal of optimal efficacy with acceptable tolerability can be attained through various avenues but requires attention on numerous moving targets, such as AEs that may occur with each drug and drug combination, potential drug-drug interactions, as well as varying levels of efficacy as the new ASM is titrated up. The high patient retention and continuous response observed from the post hoc cenobamate data, all while reducing baseline ASM doses, support the idea that the newest ASM added into a patient’s treatment regimen should not always be the focus of initial reduction. Should new or worsening central nervous system-related AEs occur during the initiation of a new ASM, a better strategy to improve efficacy and reduce overall drug burden may involve reducing concomitant drugs in the original, unsuccessful regimen, while adding on the new treatment.

 In instances where there is a known drug-drug interaction between the new ASM and an ASM in the existing regimen, proactive dose reduction of the baseline ASM may be appropriate.




ROLE OF THE PHARMACIST IN THE MANAGEMENT OF PATIENTS WITH EPILEPSY



Pharmacists provide a crucial role in patient counseling on medications and disease education, and they have the ability to perform pharmacotherapeutic monitoring for patients with chronic diseases, including epilepsy.

 Studies have shown that pharmacist interventions can improve the overall epilepsy-related health and quality of life of patients and improve medication adherence.

 For instance, pharmacist-led patient medication counseling and education can help identify and proactively alert the patient and the health care provider to potential therapeutic problems and prevent errors in dose and frequency of administration. Additionally, in the case of polytherapy in epilepsy, the pharmacist can educate the patient on their entire treatment regimen and explain how and why a new ASM is being added to their regimen. The pharmacist can help patients with epilepsy adhere to the sometimes complex instructions and prescription changes that can occur during titration of a new ASM.

 Advising patients that it may take several days or weeks to reach the full therapeutic benefit can help manage expectations. Counseling can also help mitigate the potential anxiety that patients can experience during periods of ASM changes.


Finally, pharmacists have an important role in safety counseling and monitoring for potential drug-drug interactions during ASM polytherapy. Patients should be counseled on the potential risks, such as specific tolerability issues and AEs that may arise with a new adjunctive ASM treatment. These discussions may also help the patient manage their expectations should a new or worsening AE occur, and encourage them to work with their health care provider to discuss options, such as potentially lowering the doses of other concomitant ASMs, before deciding to down-titrate or discontinue the newly added medication.


Pharmacists have unique opportunities to impact the care of patients with epilepsy, particularly those receiving polytherapy. The individualized nature of epilepsy treatment requires close monitoring and frequent communication with patients and health care providers to help patients attain the best possible therapeutic outcomes and quality of life. 

, is vice president of medical affairs for SK Life Science, Inc.



, is the director of medical information for SK Life Science, Inc.





Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. 

. 2018;75(3):279- 286. doi:10.1001/jamaneurol.2017.3949

Tian N, Boring M, Kobau R, Zack MM, Croft JB. Active epilepsy and seizure control in adults - United States, 2013 and 2015. 

. 2018;67(15):437-442. doi:10.15585/mmwr.mm6715a1

Kwan P, Brodie MJ. Early identification of refractory epilepsy. 

. 2000;342(5):314-319. doi:10.1056/NEJM200002033420503

Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive ceno­bamate (YKP3089) in patients with uncontrolled focal seizures: a mul­ticentre, double-blind, randomised, placebo-controlled, dose-response trial. 

. 2020;19(1):38-48. doi:10.1016/S1474-4422(19)30399-0

Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. 

. 2020;94(22):e2311-e2322. doi:10.1212/WNL.0000000000009530

Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. 

. 2011;52(7):1280-1291. doi:10.1111/j.1528-1167.2011.03047.x

Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy.

. 2019;3(3):CD011501. doi:10.1002/14651858.CD011501.pub2

Brigo F, Bragazzi NL, Nardone R, Trinka E. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and per­ampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs. 

. 2016;42:29-37. doi:10.1016/j.seizure.2016.08.007

Rosenfeld WE, Abou-Khalil B, Aboumatar S, et al. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. 

. Published online October 11, 2021. doi:10.1111/epi.17092

Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. 

. 2020;61(6):1099-1108. doi:10.1111/epi.16525

Sperling MR, Abou-Khalil B, Aboumatar S, et al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. 

. Published online October 11, 2021. doi:10.1111/ epi.17091

Xcopri. Prescribing information. SK Life Science, Inc; 2021. Accessed November 19, 2021. https://xcoprihcp.com/resources/pdf/SK_Prescrib­ing_Information_Med_Guide_Combined.pdf

Verrotti A, Tambucci R, Di Francesco L, et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. 

. 2020;20(2):167-173. doi:10.1080/14737175. 2020.1707668

Reis TM, Campos MS, Nagai MM, Pereira L. Contributions of pharmacists in the treatment of epilepsy: a systematic review. 

Fishman J, Cohen G, Josephson C, et al. Patient emotions and perceptions of antiepileptic drug changes and titration during treatment for epilepsy. 

. 2017;69:44-52. doi:10.1016/j.yebeh.2017.01.032

A Further Look at Rational Polytherapy in Patients With Uncontrolled Epilepsy: Insights From a Post hoc Analysis of Adjunctive Cenobamate

Diabetes management technology has advanced beyond the historical methods of manually administered insulin and glucose monitoring with either a blood glucose meter or continuous glucose monitoring (CGM).

 New technology and tools are available for patients who inject insulin to simplify diabetes management and improve glycemic control.

Insulin pump therapy is an option for patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) who need multiple daily injections (MDI) and can safely use the pump themselves or with the help of caregivers.

 Depending on their individual needs, patients can use insulin pump therapy with or without CGM to help obtain their target glycemic levels.

PATIENT CHALLENGES WITH DIABETES MANAGEMENT PLANS

Patients who experience challenges with their diabetes management plan (ie, adjusting their medication dosage to reach target blood glucose levels or experiencing discomfort with injecting insulin) may not adhere to insulin therapy and could experience regular hypoglycemic events.

 In a US-based survey of adults with T1D and T2D who inject insulin (N = 502), 57% reported skipping necessary insulin injections and 20% reported skipping them sometimes or often.

 Patients (especially those with Medicare Part D insurance) may lack access to valuable support resources, such as a community pharmacy, insurance, and device use training.

According to the American Diabetes Association (ADA), use of insulin pumps by patients who require insulin may improve satisfaction and simplify therapy.

 Pharmacists can help simplify patients’ diabetes management plan by offering support, information, training, and titration on insulin delivery devices and patch pumps, including the Omnipod DASH

 Insulin Management System is a 2-part continuous insulin delivery system consisting of the Personal Diabetes Manager (PDM; a wireless, smartphone–like controller device) and a wearable Pod that delivers insulin (

 It is easy to use, discreet, and wearable, which simplifies life by eliminating MDI and simplifying mealtime math.

When counseling patients, provide these 3 steps to start the system

 Patients or caregivers fill the Pod with rapid-acting insulin and place it almost anywhere insulin can be administered. The Omnipod DASH

 is safe for use with the following U-100 rapid-acting insulin: NovoLog

 The cannula automatically inserts and begins personalized basal insulin delivery. There is no need to touch or see the insertion needle with the auto-cannula feature, which is ideal for patients with dexterity issues or needle phobias.

 The Pod simplifies insulin delivery through bolus options in a few taps. It contains simple mealtime bolus options to meet patients where they are, using a sliding scale, counting carbohydrates, or using the built-in CalorieKing food library. Bolus presets can be based upon a sliding scale or small, medium, or large meals. The bolus calculator option allows patients to enter in grams of carbohydrates and glucose value. Also, the calculator can factor in the amount of insulin on board from a previous bolus to prevent stacking of insulin.

The results from several studies demonstrated clinical benefits in patients with T1D and T2D with the use of the Omnipod

 These studies evaluated changes in glycated hemoglobin A1c (HbA

), changes in total daily dose (TDD) of insulin, and self-reported frequency of hypoglycemic events.

Results from a multisite retrospective study (3 months [N = 3592]) showed that the percentage of patients with T2D who met the ADA-recommended target of HbA

 levels of below 7% more than doubled (10%-22%, 

 < .0001) when they switched from MDI, tubed insulin pumps, or unknown diabetes management to the Omnipod

 levels experienced a greater reduction in HbA

 at follow-up. Also, patients with prior MDI use experienced a 35-unit reduction in TDD of insulin. The weekly number of self-reported hypoglycemic events decreased from 1.2 to 0.7 (

Similarly, results from 2 separate multicenter retrospective studies (3 months [N = 873] and 12 months [N = 156]) demonstrated reductions in HbA

 among patients with T1D who switched from continuous subcutaneous insulin infusion (CSII) with tubing or MDI to the Omnipod

 System or Omnipod DASH®. Patients in the 3-month study reported significant decreases in linking to self-reported hypoglycemia frequency and severity (

Regarding quality of life, results from a survey of users with T2D showed that the top 3 reasons for switching to the Omnipod System

 were a desire for better glycemic control (25%), a desire to not be tethered to tubing (24%), and a desire to replace the discomfort and hassle of injecting (16%).

 Furthermore, responses to a survey of 140 health care professionals indicated that 74% believe Omnipod DASH

 improves adherence to pump therapy among patients with T1D and T2D switching from MDI.

As an integral part of the health care team, pharmacists can identify patients who may benefit from insulin delivery devices and technologies that help simplify diabetes management care plans. These patients may include those who are nonadherent, have not reached their target HbA

 and desire better glycemic control, or prefer to not inject insulin. Pharmacists can identify these patients by inquiring about dosage schedules, reviewing refill records, discussing patient glycemic goals, and ensuring patient understanding of treatment, injection technique, and hypoglycemia. Pharmacists may support these patients by providing education on the Omnipod DASH

Pharmacists should be aware of insurance status and affordability considerations that affect access. Omnipod DASH

 is the only full-featured insulin pump in the United States that is widely available through pharmacies. Omnipod DASH

 is covered by commercial insurance, Medicare Part D insurers, and select Medicaid programs. If pharmacy coverage is denied, medical coverage may be available. On average, the co-pay for Omnipod DASH

 through the pharmacy channel is less than $50 per month.

 Also, the average monthly out-of-pocket cost for Omnipod DASH

 Actual out-of-pocket co-pay amounts depend on patients’ health plans and coverage.

 is the only insulin pump covered through Medicare Part D, which includes coverage for both T1D and T2D (without C-peptide level tests or blood glucose logs required), a streamlined electronic fulfillment process that can reduce paperwork and expedite the Pod initiation process, co-pays that patients can pay as they go, and (typically) no switching restrictions. Convenient retail pharmacy pickup is available as well as delivery to the same pharmacy that carries the patient’s insulin. This helps provide continuity of care for patients with MDI who can benefit from Pod therapy now and when they reach 65 years of age.

Dispensing Considerations and Getting Started

, supplies the PDM free of charge with the first box of Pods. Customers will be eligible to receive 1 free PDM every 4 years with the purchase of Pods. This may be subject to certain conditions including, but not limited to, verification of insurance. Insulet also offers virtual and in-person device training, which is required for new users for individualized setup. Pharmacists can refer patients who are new users to contact Insulet at 

 to receive their PDM and schedule their training. Patients can also visit 

, including unique features, clinical guidelines, and improved outcomes data, watch 

 by Leslie Barrett, MS, RD, Senior Manager of Clinical and Professional Education at Insulet Corporation.

 Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. The Omnipod

 DASH has been tested and found to be safe for use with the following U-100 insulin: NovoLog

 for complete safety information, including indications, contraindications, warnings, cautions, and instructions. Please click 

 for Pharmacist Quick Reference Guide to Omnipod DASH.

: Average calculated based on a consumption of ten (10) Pods per month. 75,280 paid claims between January 1st, 2020 and December 31st, 2020 for commercial plans were analyzed. Actual co-pay amount depends on patient's health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis.

: Estimated total monthly out-of-pocket (OOP) for Omnipod DASH

Information For The Pharmacist

Guide to Preventative Skin Care and Importance of Sun Protection for the Community Pharmacist

A Further Look at Rational Polytherapy in Patients With Uncontrolled Epilepsy: Insights From a Post hoc Analysis of Adjunctive Cenobamate

Supporting Education on the Omnipod DASH® Insulin Management System in the Pharmacy

Role of OTC Asthma Medications in the Community Pharmacy

Supporting Sleep, Stress, and Immune Health in the Pharmacy

A Pharmacists' Guide to Recommending Prevagen®

Using Digihaler® Technology in the Community Pharmacy in Patients With Asthma

Building COVID-19 Vaccine Confidence in the Community Pharmacy

A Clinical Review of 24-Hour OTC Antihistamines for Allergy Symptom Relief

Introducing Zantac 360°™, Formulated With Famotidine